fool.com
Positivewww.fool.com ·
sera q1 2026 earnings transcript
TAX_FNCACT_WOMENTAX_FNCACT_EXECUTIVESTAX_FNCACT_FOOLSCIENCE
The full article is on the original publisher site. This page only shows the headline and a very short excerpt.
AI insight
AI-generatedSera Prognostics is a diagnostics company commercializing a preterm birth test. The Q1 2026 earnings show early-stage commercialization with minimal revenue and ongoing losses. The company is expanding provider partnerships and payer discussions, and plans European market entry via CE marking. No direct commodity or supply chain impact; the commercial mechanism is weak and limited to the company's own revenue and cost trajectory.
Signals our AI researcher identified
Extracted by our AI model from this article and related public sources — not direct quotes from the publisher.
- Revenue $14k in Q1 2026 vs $38k prior year
- Net loss $8.4 million vs $8.2 million prior year
- R&D expenses decreased to $3 million as focus shifts to commercialization
- Launched third partnership program targeting over 350 providers
- Discussions with 13 payers across 15 states; CE marking dossier submission planned midyear